MDACC Study No:2008-0604 ( NCT No: NCT00967369)
Title:A Randomized Phase II Study of Bortezomib Plus ICE (BICE) Versus Standard ICE for Patients with Relapsed/Refractory Classical Hodgkin Lymphoma
Principal Investigator:Michelle A. Fanale
Treatment Agent:Bortezomib; Carboplatin; Etoposide; Ifosfamide; MESNA
Study Status:Closed
Study Description:The goal of this clinical research study is to learn if bortezomib when given
in combination with ifosfamide, carboplatin, and etoposide (a routine
chemotherapy combination called ICE) can help to control Hodgkin's lymphoma
better than ICE when given alone. The safety of this drug combination will
also be studied.
Hide details for General InformationGeneral Information

Disease Group:Lymphoma
Phase of Study:Phase II
Treatment Agents:Bortezomib
Treatment Location:Only at MDACC
Estimated Length of Stay in Houston:Patients will be hospitalized for chemotherapy every 2 to 4 weeks for up to a
maximum of 6 cycles. It is anticipated that patients will remain in the
hospital for on average 4 to 6 days.
Supported By:Millennium Pharmaceuticals - Supporter only (Investigator-initiated study)
Return Visit:Screening, Pre-Treatment -3 days prior to each cycle 1 through 3, Day 1- Day 5
of cycle 1 through 3, Intercycle between each cycle (weekly), Response
Assessment, Follow up every 4 months for 2 years
Home Care:None

Hide details for Study Contact InformationStudy Contact Information

Physician Name:Michelle A. Fanale
For Clinical Trial Enrollment:713-792-2860
For General Questions about Clinical Trials:800-392-1611 (in U.S.A.) 713-792-6161 (outside U.S.A.)

Show details for Study Objectives / OutcomesStudy Objectives / Outcomes
Show details for Study Status InformationStudy Status Information
Show details for Enrollment EligibilityEnrollment Eligibility
Show details for Resources and LinksResources and Links
Show details for ResultsResults